Direxion Daily BRKB Bull 2X Shares (NASDAQ: BRKU)

最新ニュース Direxion Daily BRKB Bull 2X Shares (NASDAQ:BRKU)

Financial Services

The Fund, under normal circumstances, invests at least 80 percent of its net assets (plus any borrowings for investment purposes) in the securities of BRK/B and financial instruments, such as swap agreements and options, that, in combination, provide 2X daily leveraged exposure to BRK/B, consistent with the Funds investment objective. The financial instrument in which the Fund most commonly invests is swap agreements which are intended to produce economically leveraged investment results.

Gs Financial Square Treasury Instruments Fund

Dreyfus Govt Cash Man Ins

Dreyfus Trsy Prime Cash Mgmt - In 0 -

Berkshire Hathaway Inc-Cl B

Goldman Sachs Fin Gov 465 Institut

Direxion Daily BRKB Bull 2X shares

Direxion Daily BRKB Bull 2X Shares

Zscaler Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) shares are trading higher Monday on what appears to be continued momentum after the company posted better-than-expected fiscal third-quarter earnings and raised its <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45700639/zscaler-stock-is-gaining-friday-whats-going-on">full-year guidance last week</a>.
What To Know: The cybersecurity firm reported adjusted earnings of 84 cents per share, beating analyst estimates of 75 cents per share and revenue of $678 million, which topped consensus forecasts of $666.86 million.
The results were driven by demand for Zscaler&#8217;s Zero Trust Exchange platform and increased customer adoption across its portfolio. Calculated billings climbed 26% year-over-year to $785 million, exceeding expectations. Annual recurring revenue (ARR) also grew 23% year-over-year to $2.9 billion.
Despite the positive results, Piper Sandler downgraded the stock to Neutral from Overweight, citing valuation concerns and potential risks tied to Zscaler&#8217;s recent Red Canary acquisition and federal sector uncertainty. Still, the firm raised its price target from $235 to $260.
Other analysts were more bullish. RBC, KeyBanc, Needham and Rosenblatt all increased their price targets, with Rosenblatt pushing its forecast to $315. Analysts highlighted Zscaler&#8217;s strong execution, growing momentum in key product areas like Zero Trust and AI-driven security and improving sales productivity. Several firms also noted the company did not report any negative impact from current tariffs, a positive sign in the current macro environment. Positive analyst changes continue to roll in this week with Canaccord Genuity lifting its target from $230 to $305.
Zscaler's management raised full-year 2025 revenue guidance to a range of $2.659 billion to $2.661 billion, slightly above analyst estimates. Full-year adjusted earnings are now expected to be between $3.18 and $3.19 per share, up from prior forecasts and well ahead of the Street&#8217;s $3.07 estimate.
ZS Price Action: Zscaler shares were up 5.89% at $291.94 at the time of writing. Zscaler shares are now up more than 61% year-to-date. The stock climbed to new 52-week highs on Monday, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/06/45724821/trumps-manufacturing-narrative-weakens-as-may-data-shows-sharper-contraction-stubborn-inflation">Trump&#8217;s Manufacturing Narrative Weakens As May Data Shows Sharper Contraction, Stubborn Inflation </a></li>
</ul>
Image via Shutterstock.

News

Price Target

Movers

Zscaler Shares Hit New 52-Week High: What's Driving The Momentum?

<ul class="wp-block-list">
<li>The U.S. has the largest number of high-net-worth individuals, according to a new report from Henley &amp; Partners and New World Health</li>
<li>37% of the global millionaire population, 36% of the world's centimillionaires, and 33% of billionaires call the country home</li>
<li>These ultra-wealthy individuals primarily live in or near major cities like New York, San Francisco, and Los Angeles</li>
</ul>
The U.S. is home to 37% of the global millionaire total, according to a new report from Henley &amp; Partners and New World Wealth.
The <a href="https://www.henleyglobal.com/newsroom/press-releases/usa-wealth-report-2025">USA Wealth Report</a> says that over 6 million high net worth individuals, defined as those with investable assets of $1 million or more, resided in the U.S. at the end of 2024. Additionally, 36% of the world's centimillionaires and 33% of the world's billionaires also call the country home.
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>. </li>
</ul>
Over the past decade, the U.S. has seen its millionaire population increase by 78%. This growth slightly outpaces China, which saw its millionaire population increase by 74% between 2014 and 2024, and well outpaces other wealthy countries like Japan (5%), Canada (26%), Switzerland (28%), and the UK (-9%).&nbsp;
Tim Klatte, partner at Grant Thornton China, warns high net worth individuals that despite this incredible growth rate, they shouldn't get too comfortable. "The U.S.–China trade war is more than an economic battle — it is a complex geopolitical contest with far-reaching consequences," he said in a statement accompanying the report. "HNW investors must account for the risk of escalating tensions, potential breakdowns in trade negotiations, and the broader threat of international conflict. These geopolitical dynamics can significantly influence investment decisions, asset allocation, and long-term wealth preservation."
Trending: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
In fact, this economic unrest has led many ultra-wealthy Americans to explore their options when it comes to moving their wealth outside the US. According to the report, US citizens account for over 30% of all investment migration applications submitted through Henley &amp; Partners at this point in the year. A number that is nearly double the combined total of the next five investor nationalities, which include Turkish, Indian, and British.
"We're witnessing a new level of sophistication in how affluent Americans manage and diversify their wealth," says Basil Mohr-Elzeki, managing partner at Henley &amp; Partners North America. "Securing alternative residences and citizenships is now a strategic form of risk management — a thoughtful ‘Plan B' that enhances family resilience, unlocks global opportunities, and safeguards multigenerational legacies."
See Also: <a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a>
Within the U.S., high net worth individuals tend to congregate in areas the report calls "urban wealth hubs." New York City has the highest number of high net worth individuals, with 384,500 millionaires, 818 centimillionaires, and 66 billionaires. The San Francisco Bay Area, which includes Silicon Valley, is second with 342,400 millionaires, 756 centimillionaires, and 82 billionaires. Los Angeles, Chicago, and Dallas round out the top five.
"Despite a wave of policy changes and their subsequent implications around the world, the relative political stability, rule of law, economic prospects, culture of innovation, not to mention the US dollar remaining the global reserve currency, have squarely positioned the USA as an environment in which to do business and to invest," said David K. Young, president at the Committee for Economic Development of The Conference Board in a statement accompanying the report.
Read Next: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
Image: Shutterstock

Personal Finance

37% Of The World's Millionaires Call The US Home, Up 78% Over The Last Decade

WIIM

RIVN

Rivian Automotive shares are trading lower after the company announced a proposed $1.25 billion senior secured green notes offering.

Scotiabank analyst Louise Chen downgrades Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from Sector Outperform to Sector Perform and announces $135 price target.

Downgrades

Analyst Ratings

BPMC

Scotiabank Downgrades Blueprint Medicines to Sector Perform, Announces $135 Price Target

CGAU

RGLD

SSRM

USAU

Shares of precious metals stocks are trading higher as gold and silver prices rise amid dollar weakness.

JP Morgan analyst Brian Cheng downgrades Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from Overweight to Neutral and lowers the price target from $130 to $129.

JP Morgan Downgrades Blueprint Medicines to Neutral, Lowers Price Target to $129

<a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44300120/binance-ceo-richard-teng-hails-donald-trumps-bitcoin-reserve-xrp-ethereum-solana-digital-asset-stockpile">Binance CEO Richard Teng</a> on Monday said the United States is &#8220;firmly back in the driver's seat&#8221; to lead the global crypto industry, following a major regulatory development that saw U.S. authorities drop a lawsuit against the crypto exchange and its founder Changpeng Zhao.
What Happened: "This is a significant win not just for Binance, but for the entire industry," Teng said during an <a href="https://www.cnbc.com/video/2025/06/02/binance-ceo-richard-teng-on-sec-suit-dismissal-trump-meme-coin-and-crypto-regulation.html?__source=sharebar&#x7C;twitter&amp;par=sharebar">interview</a> with CNBC. "The U.S. is firmly back in the driver's seat to become the crypto hub of the world."
Teng credited the shift to the regulatory approach taken by the current administration, praising what he called a "considerate and thoughtful" stance that favors regulatory clarity over enforcement-first tactics.
The CFTC's original complaint had accused Binance of allowing illegal access to U.S. users, inflating trading volumes, and co-mingling customer funds. 
Its dismissal now marks a turning point in the broader U.S. regulatory landscape, according to the CEO.
Looking ahead, Teng expressed optimism about bipartisan efforts to create clear rules for the industry, stating that greater clarity will benefit investors, companies and regulators alike.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45718017/nothing-stops-this-train-us-fiscal-deficits-drive-bitcoins-case-as-a-hedge-says-lyn-alden">&#8216;Nothing Stops This Train&#8217;: US Fiscal Deficits Drive Bitcoin&#8217;s Case As A Hedge, Says Lyn Alden</a>
"We are deeply supportive of a regulatory framework that protects users," he said, citing Binance's milestone of surpassing 275 million global users.
Teng also addressed concerns over the proliferation of meme coins tied to political figures like President Donald Trump. 
While avoiding direct comment on their legitimacy, Teng emphasized the decentralized and permissionless nature of token creation in crypto.
Beyond the legal developments, Teng highlighted Binance's growing compliance infrastructure. 
The platform now employs over 1,400 people in its compliance division and is regulated in more than 22 countries.
"We are the most regulated global platform today," Teng said. "Our focus is on security, compliance, and user protection."
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/05/45708417/110m-wiped-out-bitcoin-whale-trader-gets-burned-as-btc-tags-104-150">$110M Wiped Out: Bitcoin Whale Trader Gets Burned As BTC Tags $104,150</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

US Is Poised To Become Global Crypto Hub After Regulatory Breakthrough, Binance CEO Says

Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) shares are trading higher Monday after the company announced its new COVID-19 vaccine secured clearance from the U.S. Food and Drug Administration (FDA) for seniors and <a href="https://www.benzinga.com//node/45708511">at-risk individuals.</a>
What To Know: In a Phase 3 clinical trial, the new vaccine, mNEXSPIKE, showed a higher vaccine efficacy as well as a similar safety profile compared to the company&#8217;s original COVID-19 vaccine. 
&#8220;The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19,&#8221; said Stéphane Bancel, CEO of Moderna.
&#8220;COVID-19 remains a serious public health threat, with more than 47,000 Americans dying from the virus last year alone. We appreciate the FDA&#8217;s timely review and thank the entire Moderna team for their hard work and continued commitment to public health.&#8221;
Moderna expects to have mNEXSPIKE available for eligible populations in the U.S. for the 2025-2026 respiratory virus season. The new vaccine is under review with regulators in multiple markets around the world.
See Also: <a href="https://www.benzinga.com/news/25/06/45727221/vera-therapeutics-applied-digital-kymera-therapeutics-and-other-big-stocks-moving-higher-on-monday">Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday</a>
MRNA Price Action: At the time of writing, Moderna stock is trading 2.73% higher at $27.28, according to data from <a href="https://pro.benzinga.com/">Benzinga Pro.</a>
Image: Shutterstock.

MRNA

Moderna Stock Is Trading Higher Monday: What's Going On?

As crypto adoption continues to grow, how individuals trade, not what they trade, has become the focus. While centralized platforms remain popular for convenience, they expose traders to more risk than is necessary.
More investors are looking for how to maintain full control of their crypto assets while minimizing exposure to third parties. One solution is necessary, decentralized crypto swaps, for example exchanging BTC for USDT. &nbsp;&nbsp;
The Problem with Centralized Swap Brokers
Most wallet-based swap interfaces, software or hardware, use centralized intermediary brokers to process transactions at present.
While the services are quick and convenient, they also expose:
• Counterparty risk, Funds are in the control of a third party temporarily during the swap.
• Privacy trade-offs, KYC requirements can force users to reveal sensitive personal information.
• Higher fees and slippage, Centralized services are more costly than decentralized alternatives.
For security-minded traders and long-term investors, these compromises are becoming ever harder to make.
Why Decentralized Swaps Offer a Better Alternative
Protocols that facilitate decentralized trading infrastructure, and wallet-to-wallet transactions without surrendering custody or personal data are the future.
Such solutions should also:
• Reduce reliance on any one central authority,
• Improve fee transparency and access to greater liquidity,
• More accurately reflect the underlying basis of crypto, decentralization and user sovereignty
Other wallet providers are beginning to recognize the value of natively embedding such decentralized protocols on their platforms, and user demand is only growing.
A Quantum Threat to Security Is on the Horizon
In addition to swap risk, another long-term problem is now taking shape, quantum computing.
Some experts, including venture capitalist Chamath Palihapitiya, are sounding the alarm that quantum developments can arrive as soon as 5 to 10 years from now, with the potential to break the encryption that safeguards today&#8217;s digital assets.
While it remains one of the most secure ways to hold crypto, exposure during swaps, especially with third parties, could be an entry point of vulnerability in the future.
Security-aware users are already adopting best practices such as:
• Never using the same exact address for multiple transactions. Use a wallet that generates a new one each time.
• Minimizing exposure to third-party custodians,
• Utilizing wallets and protocols that support decentralized infrastructure
As quantum abilities reach maturity, decentralization will not just enhance privacy and autonomy but may also turn into a default line of defense.
The Bottom Line
Integrating decentralized swap protocols into wallet ecosystems isn&#8217;t just a UX enhancement, it&#8217;s a long-term move towards privacy, affordability, and improved personal security.
For cryptocurrency traders wanting to stay ahead of both market risk and technological developments, solutions that adopt underlying decentralized principles are more important than ever.
The author has an investment in BTC.
&#x2A;&#x2A;
We at <a href="https://cryptoflowzone.com/">https://cryptoflowzone.com/</a> will continue to monitor and evaluate developments in this space to help traders make the correct choices. We also expect to pressure cold wallet providers to develop decentralized swap protocols within their solution, and offer investors a safer way of broadcast transacting in the future. Keep your eyes on the prize and Trade safe.

Opinion

Why Decentralized Swaps Are The Next Frontier For Secure Crypto Trading

Piper Sandler analyst Paul Newsome initiated coverage on Aspen Insurance Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHL#NYSE">AHL</a>) with an Overweight rating and <a href="https://www.benzinga.com/quote/ahl/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $40</a>.
The company&#8217;s IPO took place on May 8 on the NYSE exchange and it offered shares at a price of $30 per share with an insider lock-up period of 180 days<a href="https://www.benzinga.com//node/45329236" target="_blank" rel="noreferrer noopener"> that ends on November 04, 2025</a>.
The analyst writes that AHL is a reasonably profitable specialty insurer and reinsurer and he anticipates a recently completed business transformation to facilitate future growth and improved profitability.
Newsome notes that the company underwent a significant restructuring following its acquisition by Apollo in 2019.
The analyst adds that despite divesting approximately 17 business lines across its insurance and reinsurance segments, the company has reported notable improvements in its underwriting profitability and Gross Written Premium (GWP) growth.
The analyst highlights that this transformation has reduced volatility in its underwriting performance. Also, operating Return on Equity (ROE) reached 19.4% in 2024, with a three-year average of 17.1%.
Moreover, the company has seen substantial gains in underwriting profitability, and the combined ratio improved from 98.8% in 2021 to 88.0% in 2024, according to the analyst.
Newsome says that this enhanced underwriting performance is primarily attributed to a reduction in the expense ratio, an improving underlying loss ratio, and better management of catastrophe loss risks.
Overall, the analyst believes that the company warrants a slight premium valuation compared to its reinsurance peer group, given that its specialty business accounts for approximately 60% of its gross written premiums.
The analyst estimates the EPS of $3.61 for FY25 and $4.97 for FY26.
Price Action: AHL shares are up 0.81% at $34.69  at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com//node/45196561" target="_blank" rel="noreferrer noopener">Loews Posts Mixed&nbsp;Q1&nbsp;Results: Pipeline Strength Offsets Insurance And Hotel Weakness</a></li>
</ul>
Photo: Shutterstock

Initiation

Aspen Insurance Emerges From Turnaround With Momentum: Analyst Sees More Upside Ahead

<a href="https://www.chicagofed.org/publications/speeches/2025/june-2-quad-cities-business-journal" title="https://www.chicagofed.org/publications/speeches/2025/june-2-quad-cities-business-journal">https://www.chicagofed.org/publications/speeches/2025/june-2-quad-cities-business-journal</a>

Macro Economic Events

Economics

Federal Reserve

Fed's Goolsbee Says Recent PCE Inflation Print May Have Been 'Last Vestige' Of Pre-Tariff Impact

Oppenheimer analyst Andreas Argyrides assumes Harmony Biosciences Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRMY#NASDAQ">HRMY</a>) with a Outperform rating and announces Price Target of $61.

HRMY

Oppenheimer Assumes Harmony Biosciences Hldgs at Outperform, Announces Price Target of $61

AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) on Monday released results from <a href="https://www.benzinga.com/general/health-care">three Phase 3 clinical trials</a> at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting: DESTINY-Breast09, MATTERHORN, and SERENA-6.
In the DESTINY-Breast09 trial, Enhertu (trastuzumab deruxtecan) combined with pertuzumab was evaluated as a first-line treatment for HER2-positive metastatic breast cancer, compared to a standard regimen of a taxane, trastuzumab, and pertuzumab (THP). 
Topline data <a href="https://www.benzinga.com/general/biotech/25/04/44894989/astrazeneca-daiichi-sankyos-multi-billion-dollar-cancer-drug-shows-superior-efficacy-across-broad" target="_blank" rel="noreferrer noopener">were shared in April</a>.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/05/45168310/astrazenecas-triple-combination-therapy-breztri-hits-primary-goals-in-two-pivotal-studies-for-asthma" target="_blank" rel="noreferrer noopener">AstraZeneca&#8217;s Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma</a>
Results indicated that the <a href="https://www.astrazeneca.com/media-centre/press-releases/2025/enhertu-plus-pertuzumab-reduced-the-risk-of-disease-progression-or-death-vs-thp-as-1st-line-therapy-in-patients-with-her2-positive-metastatic-breast-cancer.html">Enhertu</a> combination reduced the risk of disease progression or death by 44%. Median progression-free survival (PFS) reached 40.7 months with the Enhertu regimen versus 26.9 months for THP, a benefit observed across patient subgroups.
Investigator-assessed median PFS was 40.7 months for the Enhertu arm and 20.7 months for THP. The confirmed objective response rate was 85.1% for the Enhertu combination and 78.6% for THP, with 58 complete responses in the Enhertu group compared to 33 with THP. 
The median duration of response was 39.2 months for the Enhertu combination and 26.4 months for THP. Overall survival data was not yet mature, though an early trend favored the Enhertu combination.
The MATTERHORN trial assessed <a href="http://astrazeneca-us.com/media/press-releases/2025/IMFINZI-durvalumab-regimen-reduced-risk-of-progression-recurrence-or-death-by-29-percent-in-early-stage-gastric-cancer-vs-chemotherapy-alone-in-MATTERHORN-Phase-III-trial.html?utm_source=external-comms&amp;utm_medium=memo&amp;utm_campaign=asco2025&amp;utm_term=corporate&amp;utm_content=matterhorn">Imfinzi</a> (durvalumab) with standard FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) chemotherapy as a perioperative treatment for resectable, early-stage, and locally advanced gastric and gastroesophageal junction (GEJ) cancers, compared to chemotherapy alone.
Topline data <a href="https://www.benzinga.com/general/biotech/25/03/44188407/astrazenecas-imfinzi-based-regimen-shows-improved-event-free-survival-in-early-stage-gastric-canc" target="_blank" rel="noreferrer noopener">were released in March</a>.
A planned interim analysis showed that the Imfinzi-based regimen led to a 29% reduction in the risk of disease progression, recurrence, or death. 
Median event-free survival (EFS) was not reached in the Imfinzi arm, compared to 32.8 months in the chemotherapy-alone arm. The estimated 24-month EFS rate was 67.4% for the Imfinzi regimen and 58.5% for chemotherapy alone. 
A trend towards improved overall survival was noted for the Imfinzi-based regimen, with formal assessment to follow.
The SERENA-6 trial investigated <a href="https://www.astrazeneca-us.com/media/press-releases/2025/Camizestrant-reduced-the-risk-of-disease-progression-or-death-by-56-in-patients-with-advanced-HR-positive-breast-cancer-with-an-emergent-ESR1-tumor-mutation-in-SERENA-6-Phase-III-trial.html?utm_source=external-comms&amp;utm_medium=memo&amp;utm_campaign=asco2025&amp;utm_term=corporate&amp;utm_content=serena-6">camizestrant</a> combined with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) in patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer whose tumors developed an ESR1 mutation during first-line treatment with an aromatase inhibitor (AI) and a CDK4/6 inhibitor.
Topline data were <a href="https://www.benzinga.com/25/02/43975577/astrazenecas-investigational-cancer-drug-shows-first-line-benefit-in-combination-with-widely-cancer-medicines" target="_blank" rel="noreferrer noopener">shared in February</a>.
The trial compared switching to the camizestrant combination against continuing the AI plus CDK4/6 inhibitor. The camizestrant combination reduced the risk of disease progression or death by 56%. 
Median PFS was 16.0 months for patients who switched, versus 9.2 months for those continuing the AI combination. The median time to deterioration of global health status was 23.0 months for the camizestrant arm and 6.4 months for the AI combination arm. 
While data for time to second disease progression and overall survival were immature, a trend favored the camizestrant combination for PFS2.
Price Action: AZN stock is trading lower by 0.95% at $72.14 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45726872/regeneron-experimental-weight-loss-drug-with-novo-nordisks-wegovy-helps-preserve-lean-mass-in-mid-stage-study" target="_blank" rel="noreferrer noopener">Regeneron&#8217;s Obesity Trial With Novo Nordisk&#8217;s Wegovy Hits Lean Target</a></li>
</ul>
Photo by Piotr Swat Shutterstock

Biotech

Large Cap

Health Care

General

AstraZeneca Highlights Significant Gains Across Three Major Cancer Trials At ASCO

Meta Platforms shares are trading higher amid reports that the company is planning to fully automate making of ads using AI.

Oppenheimer analyst Andreas Argyrides assumes Aquestive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQST#NASDAQ">AQST</a>) with a Outperform rating and lowers Price Target of $7.

AQST

Oppenheimer Assumes Aquestive Therapeutics at Outperform, Lowers Price Target of $7

Shares of Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) are trading lower Monday as the company faces growing pressure from Chinese electric vehicle competitors, which posted strong <a href="https://www.benzinga.com/markets/eurozone/25/05/45616006/teslas-european-woes-see-no-end-april-sales-crash-49-as-rivals-race-ahead-in-ev-market">delivery numbers for May</a>.
What To Know: Tesla&#8217;s rivals, BYD, Li Auto, Nio and Xpeng, saw <a href="https://www.benzinga.com/news/topics/25/06/45716179/teslas-china-sales-slump-while-byd-and-li-auto-post-strong-gains-report">sales growth in China</a> last month. Li Auto reported a 17% month-over-month increase, delivering 40,856 vehicles. Nio followed with over 33,500 deliveries and Xpeng delivered more than 23,000 units. BYD led the group with 204,369 battery electric vehicle deliveries in May, representing a 40% year-over-year increase.
Meanwhile Tesla has battled declining sales in the region after reporting roughly 58,000 vehicle sales in China in April, including exports. The company&#8217;s sales in the first eight weeks of second quarter have declined 23% year-over-year, suggesting continued softness in its second-largest market. Despite improving registration numbers in May — over 11,000 units registered in China for two consecutive weeks — the broader trend remains negative.
Tesla&#8217;s challenges extend beyond China. In Europe, the company posted a steep 49% drop in sales for April. For the first time, BYD surpassed Tesla in the region, signaling a significant shift in EV market dynamics.
Investors are watching closely as Tesla approaches its June 12 Robotaxi unveiling in Austin, a potential catalyst for the EV stock. 
Tesla CEO Elon Musk said last month that all that matters for the company long term are autonomy and the company's Optimus bots, which are expected to &#8220;overwhelmingly dominate the future financial success of the company.&#8221;
Analysts remain cautiously optimistic given Tesla&#8217;s advancements in Full Self-Driving (FSD) technology. However, questions linger about the company&#8217;s ability to maintain competitive footing amid rising global competition and aggressive pricing strategies, especially in China.
Despite the concerns about sales, Tesla shares have climbed about 20% over the past month as Musk&#8217;s time as a <a href="https://www.benzinga.com/25/05/45668119/tesla-rides-a-bullish-wave-as-byd-slashes-prices-whos-really-winning-the-ev-war" target="_blank" rel="noreferrer noopener">special government employee</a> comes to a close. Musk joined the Trump administration earlier this year to take a lead role at the Department of Government Efficiency, or DOGE. He announced that he was <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45672177/whats-going-on-with-tesla-stock-thursday">officially stepping away</a> from the position last week.
TSLA Price Action: Tesla shares were down 2.59% at $337.47 at the time of publication Monday, according to<a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"> Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/06/45724821/trumps-manufacturing-narrative-weakens-as-may-data-shows-sharper-contraction-stubborn-inflation">Trump&#8217;s Manufacturing Narrative Weakens As May Data Shows Sharper Contraction, Stubborn Inflation </a></li>
</ul>
Image via Shutterstock.

TSLA

Tesla Stock Is Trading Lower Today: What's Going On?

Gold is trading higher amid dollar weakness and trade policy uncertainty.

Fed's Goolsbee Says Still Think Underneath All The Tariff 'Dirt In The Air,' Rates Can Come Down Over 12-18 Months; Still Think If We Can Get Past This Bumpy Period, Dual Mandate Looks Pretty Good; A Little Gun-Shy About Arguing That Tariffs Will Have A Transitory Effect On Inflation

UBS Group expressed optimism <a href="https://www.benzinga.com/topic/chinese-stocks" target="_blank" rel="noreferrer noopener">about Chinese stocks</a>, citing the recent tariff pause with the U.S., potential stimulus measures from Beijing and attractive low valuations as key drivers.
UBS&#8217; stance coincided with a market sell-off in U.S. equities amid trade tensions, SCMP <a href="https://www.scmp.com/business/banking-finance/article/3312525/ubs-upbeat-china-stocks-citing-tariff-pause-us-and-potential-beijing-stimulus" target="_blank" rel="noreferrer noopener">reported</a> on Monday.
Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) is considered a tech barometer of China. Other significant U.S.-listed Chinese stocks included Baidu, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>), JD.Com, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>), and PDD Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>).
Also Read: <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45703311/us-listed-chinese-stocks-drop-after-trump-renews-trade-tensions" target="_blank" rel="noreferrer noopener">US Listed Chinese Stocks Drop After Trump Renews Trade Tensions</a>
Neil Hosie of UBS said Beijing&#8217;s economic policy measures in September and the emergence of artificial intelligence start-up DeepSeek&#8217;s affordable models sparked global investor interest in China equities, slowly translating into more significant fund flows.
Hosie said a 90-day tariff truce and Beijing&#8217;s hopes for domestic stimulus have translated into higher inflows into China&#8217;s markets.
Additionally, Hosie said Hong Kong&#8217;s resurgent initial public offering (IPO) market was a positive driver.
Meanwhile, Hosie said U.S. stocks were overvalued, citing the Nasdaq&#8217;s P/E of 31.70x, compared to Hong Kong&#8217;s benchmark Hang Seng Index at 10.86x and Shanghai&#8217;s main board at 15.60x, as per Bloomberg data.
Mainland Chinese households held 160 trillion yuan ($22 trillion) in cash, mostly invested in bank time deposits and about a third of it could flow into stock markets in Hong Kong as lower interest rates drive demand for riskier assets, SCMP <a href="https://www.scmp.com/business/china-business/article/3312751/chinese-households-set-buy-another-us100-billion-hong-kong-stocks-hsbc-says" target="_blank" rel="noreferrer noopener">reported</a> on Monday, citing HSBC.
Herald van der Linde, head of HSBC Asia-Pacific equity research, told SCMP that close to 50 trillion yuan, deemed excess savings over the COVID-19 pandemic years, will find their way back into local and offshore equity markets.
HSBC said Chinese investors channeled $80 billion in net inflows into Hong Kong stocks through Stock Connect&#8217;s southbound channel in 2025. At the current rate, they could funnel more excess savings to drive purchases to $180 billion by the end of the year.
HSBC said most of the cash flowing into Hong Kong&#8217;s stock market had gone into high-growth sectors such as internet firms, electric vehicle (EV) makers, and other high-yielding companies like Tencent Holdings and Alibaba.
BABA Price Actions: BABA stock is up 0.76% at $114.70 at publication on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/asia/25/05/45692725/alibaba-and-baidu-turn-to-chinese-ai-chips-as-us-sanctions-squeeze-nvidia-supply" target="_blank" rel="noreferrer noopener">Alibaba And Baidu Turn To Chinese AI Chips As US Sanctions Squeeze Nvidia Supply</a></li>
</ul>
Photo: Shutterstock

Trading Ideas

BABA

BIDU

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Comments

Direxion Daily BRKB Bull 2X Shares

ニュース

最新ニュース Direxion Daily BRKB Bull 2X Shares (NASDAQ:BRKU)

ニュース

パートナーシップ

ベンジンガ・グローバル